

**Freedom of Information Act 2000 – Request Reference FOI/24/421**

**Oncology**

**Information Requested:**

Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment

Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Carboplatin single agent or in any other combination
- Carboplatin with Gemcitabine
- Carboplatin with Paclitaxel
- Cisplatin single agent or in any other combination
- Cisplatin with Gemcitabine
- Cisplatin with Gemcitabine + Nivolumab (Opdivo)
- Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Other active systemic anti-cancer therapy
- Palliative care only

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy

**Response Details:**

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under section 16 of the Freedom of Information Act 2000, which provides a public authority with the duty to advise and assist, the UHB can inform you that your request should be directed to: [FOI.VUNHST@wales.nhs.uk](mailto:FOI.VUNHST@wales.nhs.uk).